ARTICLE | Clinical News
GS-6624: Phase II started
February 13, 2012 8:00 AM UTC
Gilead began a double-blind, U.S. Phase II trial to compare 200 and 700 mg weekly GS-6624 plus gemcitabine vs. gemcitabine plus placebo in about 244 patients with metastatic pancreatic adenocarcinoma....